The global CXC chemokine receptor market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). CXC chemokine receptors are integral membrane proteins of the CXC chemokine family and are specifically bound to them. They are a large family of G protein-linked receptors known as seven transmembranes (7-TM) proteins as they span the cell membrane seven times. Additionally, there are six types of  CXC chemokine receptors named CXCR1 to CXCR6. The major factor for the growth of the global CXC chemokine receptor market during the forecast period is the increasing prevalence of cancer across the globe.

According to the National Cancer Institute (NCI), it was estimated that 1,806,590 new cases of cancer will be diagnosed in the US with a mortality rate of 606,520 people in 2020. In men, prostate, lung, and colorectal cancers will account for an estimated 43% of all cancers diagnosed while for women, the three most common cancers are breast, lung, and colorectal which will account for an estimated 50% of all new cancer diagnoses in women in 2020.  Furthermore, there were 18.1 million new cases and 9.5 million cancer-related mortalities globally in 2018 which is anticipated to rise to 29.5 million and the number of cancer-related mortalities to 16.4 million by 2040. Hence, the rising prevalence of cancer is increasing the demand for CXC chemokine receptors owing to its growing application in the treatment of cancer which in turn is driving the growth of the market.

Some major players in the market include GlaxoSmithKline Plc, AstraZeneca Plc, and Novartis International AG, among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in August 2021, Aristea Therapeutics received $123 million in investment for the clinical development of its pipeline candidate RIST4721. It is an oral CXC chemokine receptor 2 (CXCR2) antagonist that is being developed for the treatment of palmoplantar pustulosis (PPP) and possibly other neutrophil-mediated diseases.

Market Coverage

    • The market number available for – 2020-2027

    • Base year- 2020

    • Forecast period- 2021-2027

    • Segment Covered- 

o By Type

o By Application

• Regions Covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

    • Competitive Landscape- GlaxoSmithKline Plc, AstraZeneca Plc, and Novartis International AG, among others.

Key questions addressed by the report

    • What is the market growth rate?

    • Which segment and region dominate the market in the base year?

    • Which segment and region will project the fastest growth in the market?

    • How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

    • Who is the leader in the market?

    • How players are addressing challenges to sustain growth?

    • Where is the investment opportunity?

Global CXC Chemokine Receptor Market Report by Segment

By Type 

    • CXCR1

    • CXCR2

    • CXCR3

    • CXCR4

    • CXCR5

    • CXCR6

By Application

    • Wound Healing

    • Cancer

    • HIV/AIDS

    • Others

Global CXC Chemokine Receptor Market Report by Region

North America

    • United States

    • Canada

Europe

    • UK

    • Germany

    • Italy

    • Spain

    • France

    • Rest of Europe 

Asia-Pacific

    • China

    • India

    • Japan

    • South Korea

    • Rest of Asia-Pacific 

Rest of the World

    • Latin America 

    • Middle East & Africa